Literature DB >> 30898428

Remission in dystonia - Systematic review of the literature and meta-analysis.

Tina Mainka1, Roberto Erro2, John Rothwell3, Andrea A Kühn1, Kailash P Bhatia3, Christos Ganos4.   

Abstract

In isolated, sporadic dystonia, it has been occasionally reported that some patients might undergo symptom remission. However, the exact clinical characteristics of patients with remission remain understudied. Given the important prognostic and pathophysiological implications of dystonic remission, we here provide a systematic review of the literature and a meta-analysis to assess demographic and clinical features associated with this phenomenon. We also provide a list of operational criteria to better define dystonic remission. Using PubMed and Embase, we conducted a systematic literature search in March 2018. 626 records were screened, 31 studies comprising data of 2551 cases with reports predominantly from patients with cervical dystonia (n = 1319) or blepharospasm/Meige syndrome (n = 704) were included in qualitative analysis. Five studies reporting remission in cervical dystonia were eligible for meta-analysis. Complete remission was reported in 11.8% and partial remission for 4.4% of cases. Remission rates were higher in cervical dystonia than in blepharospasm/Meige (e.g. complete remission 15.4% vs. 5.8% respectively). Remission occurred on average 4.5 years after onset of dystonic symptoms. However, the majority of patients (63.8%) relapsed. Meta-analysis for cervical dystonia showed that patients with remission were significantly younger at symptom onset than patients without remission (mean difference -7.13 years [95% CI: 10.58, -3.68], p < 0.0001). Based on our findings, we propose that the degree, the conditions associated with the onset, and the duration of remission are key factors to be considered in a unifying definition of dystonic remission.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Blepharospasm; Dystonia; Recovery; Remission; Torticollis

Mesh:

Year:  2019        PMID: 30898428     DOI: 10.1016/j.parkreldis.2019.02.020

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  6 in total

Review 1.  Cannabinoids and dystonia: an issue yet to be defined.

Authors:  Marcello Mario Mascia; Daniele Carmagnini; Giovanni Defazio
Journal:  Neurol Sci       Date:  2019-12-17       Impact factor: 3.307

Review 2.  Medical and Surgical Treatments for Dystonia.

Authors:  H A Jinnah
Journal:  Neurol Clin       Date:  2020-03-02       Impact factor: 3.806

Review 3.  Botulinum Toxin in Movement Disorders: An Update.

Authors:  Charenya Anandan; Joseph Jankovic
Journal:  Toxins (Basel)       Date:  2021-01-08       Impact factor: 4.546

4.  Functional and Idiopathic Cervical Dystonia in Two Family Members: A Challenging Diagnosis.

Authors:  Elena Antelmi; Enrico Conti; Myriam Carecchio; Michele Tinazzi
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2020-12-11

5.  Functional dystonia: A case-control study and risk prediction algorithm.

Authors:  Christopher D Stephen; David L Perez; Lori B Chibnik; Nutan Sharma
Journal:  Ann Clin Transl Neurol       Date:  2021-03-16       Impact factor: 4.511

6.  The Impact of the Course of Disease before Botulinum Toxin Therapy on the Course of Treatment and Long-Term Outcome in Cervical Dystonia.

Authors:  Harald Hefter; Isabelle Schomaecker; Max Schomaecker; Dietmar Rosenthal; Sara Samadzadeh
Journal:  Toxins (Basel)       Date:  2021-07-16       Impact factor: 4.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.